Pietro Lampertico Selected Research

Tenofovir (Viread)

1/2022	Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data.
1/2022	Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B.
1/2021	Reply to: "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B".
1/2021	Editorial: similar risk of hepatocellar carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe.
11/2020	Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
10/2020	Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide.
1/2020	Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study.
1/2020	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
1/2020	Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
1/2020	Is Tenofovir Superior to Entecavir in Reducing the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B? The Controversy Continues.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pietro Lampertico Research Topics

Disease

80	Chronic Hepatitis B 01/2022 - 04/2003
60	Fibrosis (Cirrhosis) 07/2022 - 10/2004
52	Infections 01/2022 - 12/2003
44	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 08/2003
25	Hepatitis B 01/2022 - 01/2005
20	Liver Diseases (Liver Disease) 01/2022 - 08/2003
17	Chronic Hepatitis C 01/2022 - 09/2007
12	Hepatitis 01/2021 - 12/2003
9	Hepatitis C 01/2022 - 01/2009
8	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022 - 04/2003
7	Chronic Hepatitis (Chronic Active Hepatitis) 11/2022 - 10/2004
6	Liver Neoplasms (Liver Cancer) 01/2020 - 01/2009
5	Coinfection 01/2022 - 11/2015
5	Neoplasms (Cancer) 12/2021 - 06/2004
5	Inflammation (Inflammations) 10/2021 - 03/2007
5	Disease Progression 01/2021 - 12/2003
4	COVID-19 01/2022 - 11/2020
4	Chronic Renal Insufficiency 06/2021 - 09/2017
4	Proteinuria 10/2020 - 06/2018
3	Reinfection 09/2018 - 12/2003
3	Hematologic Neoplasms (Hematological Malignancy) 10/2017 - 06/2004
3	End Stage Liver Disease 01/2017 - 02/2013
3	Rheumatoid Arthritis 01/2016 - 02/2012
2	Viremia 01/2022 - 12/2015
2	Hypertension (High Blood Pressure) 11/2021 - 01/2021
2	Hemorrhage 07/2021 - 01/2011
2	Esophageal and Gastric Varices (Esophageal Varices) 07/2021 - 01/2011
2	Liver Failure 01/2021 - 07/2014
2	Alcoholic Fatty Liver 01/2021 - 06/2020
2	Fatigue 01/2021 - 11/2019
2	Persistent Infection 01/2021 - 10/2012
2	Pathologic Constriction (Stenosis) 01/2021 - 01/2019
2	Carcinoma (Carcinomatosis) 01/2021 - 08/2003
2	Portal Hypertension 01/2021 - 10/2019
2	HIV Infections (HIV Infection) 01/2020 - 01/2020
2	Alcoholism (Alcohol Abuse) 01/2020 - 01/2016
2	Hematuria 01/2020 - 06/2018
2	Virus Diseases (Viral Diseases) 01/2020 - 06/2018
2	Ascites 01/2020 - 12/2003
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2019 - 07/2014
2	Hypophosphatemia 09/2017 - 09/2011
2	Fanconi Syndrome (Syndrome, Fanconi) 09/2017 - 12/2014
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 07/2014 - 04/2006

Drug/Important Bio-Agent (IBA)

48	Antiviral Agents (Antivirals)IBA 01/2022 - 12/2009
33	Hepatitis B e AntigensIBA 01/2022 - 04/2003
26	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2022 - 02/2012
24	InterferonsIBA 01/2022 - 04/2003
24	Tenofovir (Viread)FDA Link 01/2022 - 03/2012
22	entecavir FDA Link 01/2022 - 09/2006
16	Lamivudine (Epivir)FDA Link 01/2019 - 12/2003
14	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 11/2007
10	glecaprevir and pibrentasvirIBA 01/2022 - 01/2019
8	AntigensIBA 01/2022 - 05/2005
8	Ribavirin (Virazole)FDA LinkGeneric 01/2021 - 01/2009
7	Alanine Transaminase (SGPT)IBA 11/2021 - 01/2011
7	RNA (Ribonucleic Acid)IBA 01/2020 - 06/2004
7	adefovirIBA 09/2017 - 12/2005
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2012
6	peginterferon alfa-2a (Pegasys)FDA Link 01/2020 - 01/2018
5	nasIBA 01/2022 - 04/2015
5	Sorafenib (BAY 43-9006)FDA Link 12/2021 - 08/2018
5	CreatinineIBA 11/2020 - 09/2011
5	Hepatitis B Core AntigensIBA 01/2020 - 02/2012
4	tenofovir alafenamideIBA 01/2022 - 09/2017
4	alpha-Fetoproteins (alpha-Fetoprotein)IBA 01/2022 - 01/2019
4	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022 - 04/2016
4	Pharmaceutical PreparationsIBA 01/2020 - 04/2011
4	NucleosidesIBA 12/2019 - 01/2009
4	Immunoglobulins (Immunoglobulin)IBA 10/2019 - 05/2005
3	acarboxyprothrombin (PIVKA)IBA 01/2022 - 01/2020
3	Proteins (Proteins, Gene)FDA Link 10/2021 - 01/2020
3	Rituximab (Mabthera)FDA Link 01/2019 - 07/2014
3	EnzymesIBA 01/2019 - 05/2005
3	hepatitis B hyperimmune globulinIBA 09/2018 - 12/2003
3	Transaminases (Aminotransferases)IBA 12/2016 - 09/2007
3	adefovir dipivoxil (Hepsera)FDA Link 04/2006 - 12/2003
2	bulevirtideIBA 11/2022 - 01/2022
2	Vitamin K FDA Link 01/2022 - 01/2020
2	regorafenibIBA 12/2021 - 11/2019
2	Glucose (Dextrose)FDA LinkGeneric 11/2021 - 01/2018
2	PlasticsIBA 01/2021 - 01/2019
2	Cell-Free Nucleic AcidsIBA 01/2021 - 06/2004
2	Phospholipases (Phospholipase)IBA 12/2020 - 10/2013
2	AntibodiesIBA 01/2020 - 01/2016
2	NucleotidesIBA 12/2019 - 12/2014
2	Circular DNAIBA 01/2019 - 01/2019
2	Biological ProductsIBA 01/2019 - 02/2012
2	CryoglobulinsIBA 06/2018 - 09/2007
2	lipoarabinomannan (LAM)IBA 09/2017 - 06/2012
2	InterleukinsIBA 03/2013 - 03/2007
1	F 4 (F-4)IBA 07/2022
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022
1	Prothrombin (Factor II)IBA 01/2022

Therapy/Procedure

70	Therapeutics 01/2022 - 04/2003
20	Liver Transplantation 12/2021 - 12/2003
5	Drug Therapy (Chemotherapy) 01/2019 - 04/2006
4	Duration of Therapy 12/2021 - 08/2018
3	Contraindications 01/2022 - 01/2015
2	Aftercare (After-Treatment) 01/2020 - 01/2016
1	Patient Readmission 01/2022